For a better treatment of actinic keratosis and basal cell carcinoma.
Our drug candidate AVX001, formulated as a gel is a potent and selective blocker of the cPLA2α enzyme activity leading to significantly reduction of arachidonic acid which in turn reduces tumor growth by affecting several key hallmarks of cancer development.
AVX001 is a novel small molecule, acting through a unique mechanism of action targeting cytosolic phospholipase A2-alpha (cPLA2α) and presented in an effective and cosmetically attractive gel formulation.
In previous clinical trials, AVX001 was found to be safe, well-tolerated, and demonstrated effectiveness in both psoriasis and AK.
Our goal is to conduct the phase IIa and IIb study in close collaboration with a partner company under a license agreement.
Actinic keratosis (AK) and basal cell carcinoma (BCC) are very common diseases, both skin disorders associated with overexposure of sunlight. AK is by far the most prevalent skin cancer condition affecting up to 60 million people in the US alone, and BCC is the most common type of skin cancer, with estimated 4 million new cases each year in the US alone.
There are few drug therapies available and most are associated with moderate to severe side effects. Hence we see a market opportunity for a safe and efficacious treatment with our clinically validated drug candidate AVX001.
BCC is the most common type of skin cancer with a global annual sale of 6.7 billion USD.
Erlend P. Skagseth
Chairman of the Board
John R. Zibert